Koala Chlamydia Vaccine Claims Under Scrutiny After Expert Flags ‘Dumbfounding’ Error
Groundbreaking claims of a revolutionary vaccine for koalas afflicted by deadly chlamydia are facing serious doubt, with a leading vaccine expert alleging a fundamental flaw in the research that “completely undermines” the findings. The vaccine, developed by Professor Peter Timms, a microbiologist at the University of Sunshine Coast (USC), was hailed last year as a historic breakthrough and a potential cure for one of the most significant threats to the endangered marsupial.
However, Professor Keith Chappell, a molecular virologist at the University of Queensland and a key figure behind the development of the Molecular Clamp technology used to combat COVID-19, has raised significant concerns. Professor Chappell’s unease was first sparked in 2023 when he heard Professor Timms present his research.
“I saw Professor Timms speak in 2023 and that sort of triggered some alarms for me from that very first time present because the claims he was making were not validated by the data,” Professor Chappell stated.
Initially, Professor Timms was reportedly reluctant to share his data with Professor Chappell. Upon finally gaining access, Professor Chappell expressed disbelief at the alleged oversight.
“It seems really silly to say out loud, but they’re vaccinating koalas at the age of 10 or 11 and saying the vaccine is responsible for allowing them to get to that age, rather than just the vaccine protecting them from that point forward,” Professor Chappell explained. “I had to look at the data multiple times and show it to multiple people just to convince myself that it was that simple and that crazy of a mistake that they made.”
The research has attracted substantial government funding, with the University of the Sunshine Coast receiving $749,000 from the federal government and an additional $100,000 from the Queensland government.
In response to the controversy, a spokesperson for the University of the Sunshine Coast defended Professor Timms’ work, stating, “This work, undertaken over more than a decade, reflects deep expertise, robust governance and a clear commitment to evidence-based research. Professor Timms is widely recognised nationally and internationally as a leading authority on chlamydial disease.”
The university also refuted reports suggesting a pause in the vaccine’s production. “The vaccine rollout has not been suspended, however it is not currently being used, as our manufacturing partner is in the process of producing a high-quality APVMA [Australian Pesticides and Veterinary Medicines Authority] approved standard batch of the vaccine,” the spokesperson added. They indicated that the vaccine would undergo further testing on healthy koalas if it met the required standards.
Federal Environment Minister Murray Watt had previously expressed strong support for the project, highlighting the chlamydia’s detrimental impact on wild koala populations and their fertility. “We know chlamydia impacts the fertility of wild koala populations and is a threat to their survival, that’s why the Albanese government is supporting this project,” Minister Watt had said. Professor Timms himself had stated, “We knew a single-dose vaccine – with no need for a booster – was the answer to reducing the rapid, devastating spread of this disease, which accounts for as much as half of koala deaths across wild populations in Australia.”
However, Professor Chappell’s investigation casts a shadow of doubt over the vaccine, marketed as Klavax by Sydney-based manufacturer Treidlia Biovet.
“We don’t know if it works or not, and that means more research needs to be done, and it needs to be done correctly,” Professor Chappell emphasised. “They have published a peer-reviewed placebo-controlled trial … [in that] particular trial, it showed no effect. So it doesn’t really look very good for this vaccine, it doesn’t look very promising at all.”
A university spokesperson, in a statement released on Friday, acknowledged that while Professor Timms’ study, published in the journal NPJ Vaccines, was peer-reviewed, “minor errors” had been identified. Following the removal of specific data points, the spokesperson claimed the study still indicated “a significant difference between vaccinated and unvaccinated koalas in reducing the development of disease.” However, they conceded that the trend showing protection from death was “no longer statistically significant due to the reduced sample size.”
Professor Chappell also stressed the need for a broader approach to koala conservation. “What I think we need to do is protect our natural habitat. It’s a complex issue – there’s drought, there are bushfires, there’s habitat degradation – we really need to address the underlying conditions affecting the environment and give koalas the best chance of survival,” he argued. He pointed out that millions have already been invested in tackling chlamydia without definitive success.
The University has been approached for further comment from Professor Timms.
